The initiative, backed by a total financial outlay of Rs 5,000 Crore (nearly $600 million) spanning from FY 2023-24 to FY ...

Industry experts debate if the revised Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, with a Rs ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Deal announcements often showcase where the stars align in ...

Pharmaceutical drug discovery and development have grown increasingly difficult over the years. Yes, there have been great breakthroughs in technology that can facilitate research processes and the ...

According to a new report by Deloitte’s Centre for Health Solutions, large biopharmaceutical companies are struggling to convert on their R&D investments. By one measure, annual projected pharma R&D ...

Iris brings over 30 years of global leadership in clinical development, regulatory strategy, and pharmaceutical R&D execution. From 2008 to 2024, she served as Executive Vice President, Chief Medical ...

Forbes contributors publish independent expert analyses and insights. I like biomedical innovation. And data. Not necessarily in that order. Many pharma critics argue that drug companies skimp on ...

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...

The latest announcement is out from NovaBay Pharma ( (NBY) ).

Fintel reports that on October 7, 2025, D. Boral Capital maintained coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. Analyst Price Forecast Suggests 585.48% Upside As of September 30 ...